Berliner Boersenzeitung - DR Congo drug manufacturing plan sparks safety concerns

EUR -
AED 4.241201
AFN 76.219915
ALL 93.210974
AMD 421.7986
AOA 1060.156793
ARS 1727.958172
AUD 1.63908
AWG 2.081626
AZN 1.959559
BAM 1.954403
BBD 2.32254
BDT 142.738005
BHD 0.43488
BIF 3440.896583
BMD 1.154855
BND 1.478624
BOB 14.004993
BRL 5.916207
BSD 1.153151
BTN 109.628664
BWP 15.63742
BYN 3.410563
BYR 22635.15384
BZD 2.319233
CAD 1.618125
CDF 2611.126427
CHF 0.932311
CLF 0.026733
CLP 1055.559908
CNY 7.795147
CNH 7.793913
COP 3675.544784
CRC 522.915026
CUC 1.154855
CUP 30.603652
CVE 110.186265
CZK 24.201154
DJF 205.338828
DKK 7.47541
DOP 67.250199
DZD 153.530983
EGP 57.54318
ERN 17.322822
ETB 186.117873
FJD 2.553963
FKP 0.857848
GBP 0.857774
GEL 3.019946
GGP 0.857848
GHS 13.520339
GIP 0.857848
GMD 84.878181
GNF 10128.411837
GTQ 8.795715
GYD 241.227629
HKD 9.058306
HNL 30.907112
HRK 7.534038
HTG 150.767698
HUF 362.223087
IDR 20682.294394
ILS 3.477385
IMP 0.857848
INR 109.932764
IQD 1510.627108
IRR 1587694.361999
ISK 141.792902
JEP 0.857848
JMD 183.243508
JOD 0.818791
JPY 182.181232
KES 149.439303
KGS 100.991685
KHR 4673.518854
KMF 493.12343
KRW 1638.640772
KWD 0.357023
KYD 0.961017
KZT 541.135669
LAK 26067.486096
LBP 103263.512096
LKR 386.906578
LRD 208.141271
LSL 18.917964
LTL 3.409986
LVL 0.69856
LYD 7.339597
MAD 10.74762
MDL 20.03577
MGA 4908.365176
MKD 61.481068
MMK 2424.552772
MNT 4152.673297
MOP 9.316283
MRU 46.240358
MUR 54.209096
MVR 17.842347
MWK 1999.510632
MXN 19.917775
MYR 4.721853
MZN 73.807157
NAD 18.917964
NGN 1572.381111
NIO 42.438205
NOK 11.00856
NPR 175.401109
NZD 1.964222
OMR 0.444037
PAB 1.153176
PEN 3.903611
PGK 5.170149
PHP 70.148769
PKR 320.189388
PLN 4.30117
PYG 6876.93715
QAR 4.215887
RON 5.244777
RSD 117.358631
RUB 93.515578
RWF 1693.938243
SAR 4.333626
SBD 9.317771
SCR 16.99798
SDG 693.483603
SEK 10.953417
SGD 1.479663
SLE 28.408276
SOS 659.009126
SRD 43.501064
STD 23903.162464
STN 24.481764
SVC 10.089834
SZL 18.902002
THB 38.159872
TJS 10.643495
TMT 4.041992
TND 3.383582
TRY 54.964638
TTD 7.82126
TWD 37.289687
TZS 3055.166026
UAH 51.602087
UGX 4300.926733
USD 1.154855
UYU 46.366868
UZS 13708.204675
VES 871.004473
VND 30288.376519
VUV 137.825311
WST 3.151849
XAF 655.468764
XAG 0.018606
XAU 0.000271
XCD 3.121053
XCG 2.078224
XDR 0.815196
XOF 655.474435
XPF 119.331742
YER 273.556256
ZAR 18.867557
ZMK 10395.078432
ZMW 22.01327
ZWL 371.86277
  • CMSC

    -0.0600

    21.73

    -0.28%

  • RYCEF

    0.6000

    21

    +2.86%

  • BCE

    0.0600

    22.06

    +0.27%

  • JRI

    -0.0500

    12.67

    -0.39%

  • CMSD

    0.0200

    22.04

    +0.09%

  • NGG

    -0.1600

    80.26

    -0.2%

  • GSK

    -0.0700

    51.46

    -0.14%

  • RBGPF

    0.0000

    69.74

    0%

  • BCC

    -1.6900

    84.8

    -1.99%

  • RIO

    2.5000

    101.51

    +2.46%

  • RELX

    -0.1900

    36.61

    -0.52%

  • BTI

    0.1500

    59.27

    +0.25%

  • VOD

    -0.3800

    15.31

    -2.48%

  • BP

    -1.2300

    41.21

    -2.98%

  • AZN

    5.8800

    161.5

    +3.64%

DR Congo drug manufacturing plan sparks safety concerns
DR Congo drug manufacturing plan sparks safety concerns / Photo: Barbara DEBOUT - AFP

DR Congo drug manufacturing plan sparks safety concerns

Sitting at his desk overlooking a pharmaceutical factory floor on the outskirts of the Congolese capital Kinshasa, Joss Ilunga Dijimba, 52, cracked a jovial smile.

Text size:

"It's not easy doing business in Congo," he said.

His family was forced to relocate the factory in the 1990s to survive bouts of mass looting. And nowadays, there are onerous taxes, customs duties, and problems retaining talented staff.

His company, which employs about 40 people and produces generics such as paracetamol, is one of a tiny number of drug manufacturers in the Democratic Republic of Congo, an impoverished nation roughly the size of Western Europe.

But a government plan to require hospitals and NGOs to buy more locally produced drugs could soon boost the fledgling pharmaceutical industry -- despite fears in some quarters that safety standards are far below international norms.

Several NGOs, some of which provide medical care in the DRC's conflict-torn east, have requested opt-outs.

At the small Pharmagros plant, behind barbed-wire walls near the Congo river, men in hairnets and white coats formulate medicines with imported precursor using lab equipment in airconditioned rooms.

"Promoting local industry's a good thing," said Dijimba, a University of Texas graduate, insisting that several Congolese firms, including his, maintained high standards.

"It could grow the middle class."

About 73 percent of the DRC's population of 90 million lives on under $1.9 a day, according to the World Bank. Most products in the African country are imported.

- 'At your own peril' -

The Congolese government has designated 35 drug molecules, including paracetamol, that medical facilities will be required to purchase in locally made form.

The government wants to stimulate business without banning imports, said Donatien Kabamb Kabey, the pharmaceuticals director at the DRC's health ministry.

He explained that all the molecules can be replaced with imported equivalents, suggesting that ibuprofen could replace paracetamol, for example.

Although not yet implemented, the policy already appears to be working.

Fifteen new pharma businesses are setting up in the DRC ahead of the new rules, Kabey said, which will add to the existing 24.

The policy was partly designed to encourage factories to return after fleeing the country in the 1990s, he added, when unpaid soldiers went on the rampage towards the end of ex-dictator Mobutu Sese Seko's reign.

But experts warn that Congolese-made medicines face a major challenge: reassuring doctors and patients that they meet regulatory standards.

"When you go to the private sector in Congo, you do it at your own peril," said Ed Vreeke, who runs the Belgium-based independent pharmaceutical auditing firm Quamed.

"They know darn well that the quality they produce is not good."

Vreeke said Congolese regulators had improved, but the country lacked the massive resources needed to properly perform audits, check labels, and inspect the chemical composition of drugs for safety.

Kabey, whose department at the health ministry oversees inspections, said standards had improved "enormously" in recent years, but did not provide further details.

He said the government was establishing a national quality-control lab.

- 'A huge thing' -

Shoddy or falsified medicines kill hundreds of thousands of people every year, according to the World Health Organization, mostly in poor countries.

The DRC's hot and humid climate also poses storage problems.

A 2021 study of both imported and locally produced eye drops sold in Kinshasa, for example, showed that three out of the seven products tested were substandard. The one sample manufactured in the DRC was contaminated.

Outside a pharmacy in Kinshasa's upmarket Gombe district, clutching a bag of medicines, 29-year-old corporate lawyer Joelle Mamputu said she didn't pay attention to where drugs were made but said she had "no prejudice".

However, a 52-year-old public servant named Olivier said there was "quite a difference" between Congolese and foreign drugs.

He added he would buy Congolese drugs were the quality the same.

Despite official assurances, major international NGOs such as Doctors Without Borders (MSF) and Medecins du Monde (MDM) have requested opt-outs from the purchasing requirements, several humanitarian workers said.

MSF declined to comment.

MDM confirmed it had asked for an exemption due to concerns over quality and capacity to meet demand.

"It's a huge thing," said one humanitarian who asked for anonymity, explaining that the new rules will affect all non-governmental organisations, hospitals and pharmacies.

Many aid workers understand the need to promote enterprise, he said, but there are internal disagreements about whether to compromise on quality.

"We need to have high quality standards for everyone, but the reality of the country is that sometimes it's impossible".

(U.Gruber--BBZ)